Table 1.
Buprenorphine pharmacokinetics (mean ± SEM) for IV buprenorphine, SRB, and TDB
| IV | SRB | TDB | |
| C0 or Cmax (ng/mL) | 17.7 ± 3.2 | 2.9 ± 1.0 | 0.6 ± 0.1 |
| Tmax (h) | not done | 22.2 ± 10.6 | 63 ± 3.0 |
| Tlast (h) | 15.2 ± 3.7 | 264.0 ± 32.2a | 72b |
| AUC0-Tlast (ng × h/mL) | 9.7 ± 1.4 | 221.6 ± 26.8 | 25.2 ± 3.9 |
| AUC0-∞ (ng ×h/mL) | 10.5 ± 1.6 | 261.5 ± 26.8 | not quantifiable |
| Elimination rate constant (1/h) | 0.4 ± 0.1 | 0.007 ± 0.001 | not quantifiable |
| t1/2(h) (harmonic mean) | 2.4 ± 0.9 | 102.5 ± 14.3 | not quantifiable |
| Clearance | 2.1 ± 0.4 | not quantifiable | not quantifiable |
| Mean residence time (h) | 2.2 ± 0.9 | not quantifiable | not quantifiable |
| Volume of distribution at steady state (L/kg) | 4.2 ± 1.4 | not quantifiable | not quantifiable |
Minipigs received a single administration of buprenorphine (0.02 mg/kg IV; n = 5), SRB (0.18 mg/kg SC; n = 5), or TDB (30 µg/h topical, n = 4).